French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie.\n\n\n\nJuvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. \n\n\n\nPylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections.\n\n\n\nLazard and Latham & Watkins served as financial and legal advisors for Juvisé Pharmaceuticals, whereas White & Case served as legal advisors for Société Générale.\n\n\n\nSerious gastro-intestinal disease\n\n\n\nFrédéric Mascha, founder and president of Juvisé Pharmaceuticals, said: “We are delighted to have successfully accomplished this transaction with AbbVie regarding Pylera, a high-quality medicine, crucial for patients suffering from a serious gastro-intestinal disease. We were also pleased to be able to count on the permanent and unwavering support of our long-term banking partner, Société Générale.”\n\n\n\nThe company says this is another example of Juvisé Pharmaceuticals establishing successful alliances with world class pharmaceuticals sectors. Previous transactions have been with Novartis and AstraZeneca.\n\n\n\nPylera, a 3-in-1 combination of antimicrobial products, is used for the treatment of patients with Helicobacter pylori infection and suffering from gastro-duodenal ulcer disease. The eradication of the pathogen agent has been shown to reduce the risk of peptic ulcers recurrence and gastric cancers.